Clinical Trials
4 trialsNCT04672460 2024-09-25
A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors
Pfizer
Phase 1 Completed
NCT04598321 2023-10-12
BrUOG 390: Neoadjuvant Treatment With Talazoparib
Brown University
Phase 1 Terminated
NCT03642132 2023-04-06
JAVELIN OVARIAN PARP100
Pfizer
Phase 3 Terminated
NCT02326844 2020-08-18
BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated